BILIARY TRACT CANCER

This study tests new immune-boosting drugs, alone or with other cancer treatments, in people with advanced liver or bile duct cancer. The goal is to see if these drugs can shrink tumors or slow the disease. About 294 adults whose cancer has spread or cannot be removed by surgery …

This study tests a new way to treat advanced bile duct cancer that cannot be removed by surgery. It combines chemotherapy given directly into the liver with standard body-wide chemo, plus or minus an immunotherapy drug (adebrelimab) and a targeted therapy pill (apatinib). About 1…

This study tests a combination of two experimental drugs, HX009 and IN10018, with or without standard chemotherapy, in people with advanced solid tumors like bile duct cancer and melanoma that have not responded to prior treatments. The goal is to find the best dose and see if th…

This early-phase trial tests a new drug called MDX2001 in about 285 adults with advanced solid tumors (cancers that have spread). The main goals are to check the drug's safety and find the right dose. Researchers will also see if it shrinks tumors. This is not a cure, but it may …

This study compares two immunotherapy drugs (rilvegostomig and durvalumab) combined with standard chemotherapy as a first treatment for people with advanced biliary tract cancer that cannot be removed by surgery. About 1,100 participants worldwide will be randomly assigned to one…

This study tests whether a new drug called ivonescimab works better than standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were part of a prior trial (SAFIR-ABC10) will be randomly assigne…

This study tests a new two-drug combination (trifluridine/tipiracil pills plus oxaliplatin IV) in 27 people with advanced biliary tract cancer whose first chemotherapy stopped working or didn't help. The goal is to see if this combo can keep the cancer from growing better than th…

This study tests an experimental drug called TQB2102 in about 102 people with a rare and advanced bile duct cancer that has a specific marker (HER2-positive). The goal is to see if the drug can shrink tumors and how safe it is. Participants must be between 18 and 75, have good or…

This study tests whether adding two immunotherapy drugs (tuvonralimab and iparomlimab) to standard chemotherapy before surgery helps remove bile duct cancer more completely. About 45 adults with resectable or borderline-resectable cancer will receive 2-4 cycles of treatment, then…

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) helps people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults whose cancer cannot be removed by surgery will be …

This study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults who have not had prior treatment for advanced di…

This early-phase study tests a new drug called AZD4360 in adults with advanced stomach, bile duct, or pancreatic cancers that have not responded to prior treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 117 participa…

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the standard drugs gemcitab…

This early-phase study tests a new drug called BL-M07D1 in adults with advanced HER2-positive solid tumors (including breast, lung, stomach, and ovarian cancers) that have not responded to at least two prior treatments. The main goals are to check the drug's safety, find the best…

This study tests a new drug called AZD0901, alone or with other cancer drugs, in people with advanced solid tumors that have a specific marker (CLDN18.2). The goal is to see if it is safe and shrinks tumors. About 224 adults with stomach, bile duct, or pancreatic cancer will take…

This study tests a new treatment called RP2, a virus that attacks cancer cells, combined with other drugs for people with advanced liver or bile duct cancer that has not responded to first treatment. About 60 adults will take part. The goal is to see if the combination shrinks tu…

This study is for people with biliary tract cancer who have had surgery to remove their tumor. Researchers want to see if using a special test (MiniPDX) to pick the best chemotherapy drugs can help keep the cancer from coming back. About 204 adults will take part, and the study w…

This study tests a new drug called MK-2870, alone or with other cancer treatments, in people with advanced colorectal, pancreatic, or bile duct cancers that have spread or can't be removed by surgery. The main goals are to check the drug's safety and see if it can shrink tumors. …

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have tried at least one prior therapy. The main goals are to find a safe dose and check for early signs of tumor shrinkage. About 27 adults will…

This study looks at the safety of the drug Tasfygo in people with a certain type of advanced bile duct cancer that has gotten worse after chemotherapy. About 60 participants will be watched for side effects and how well the drug works. The goal is to make sure the drug is safe fo…

This early-phase study tests a new drug, LNCB74, in about 145 people with advanced solid tumors (ovarian, breast, lung, and others). The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety and find the best dose for futur…

This study tests two experimental drugs, AK130 and AK112, for people with advanced biliary tract cancer (a type of bile duct cancer) that has not responded to other treatments. The first part checks safety and the right dose, while the second part sees if the combination can shri…

This study is testing a new drug called Dato-DXd, either alone or with other cancer drugs, in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gastric, prost…

This study tests whether two drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to standard treatments. About 64 adults will receive the drug combination to see if tumors get smaller. The goal is to find a new option fo…

This study tests a precision medicine approach for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. Participants will receive a combination of ivosidenib (a targeted pill) plus either lenvatinib or an immunotherapy drug. The goal i…

This early-stage study tests a new drug called BL-M05D1 in about 160 adults with advanced or metastatic solid tumors, including stomach, pancreatic, esophageal, and bile duct cancers. The main goals are to find safe doses and understand side effects. Participants must have tried …

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study tests a combination of two targeted drugs (trastuzumab and serplulimab) plus chemotherapy in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this triple therapy can shrink tumors and improv…

This study tests a new drug, SHR-A1904, in people with advanced bile duct cancer that has not responded to previous treatments. The drug targets a specific protein (CLDN18.2) on cancer cells. About 151 participants will receive the drug to see if it can shrink tumors or slow dise…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve daily life in people with digestive tract cancers. 360 participants will be randomly assigned to one of three groups: skills-based VR, distraction VR, or a sham VR. The goal is to see if …

This study compares three standard pain management methods used during minimally invasive cancer surgery. 48 adults having surgery for cancers of the liver, stomach, pancreas, or other organs will be randomly assigned to one of three groups. The goal is to see which method provid…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find important genetic changes in people with advanced bile duct cancer. Normally, doctors need a tissue sample from the tumor, which can be hard to get. The study will enroll 100 adults in Korea and …

This study looks at whether a blood test that detects tiny bits of tumor DNA (called ctDNA) can help doctors better manage gastrointestinal cancers like pancreas, colon, and bile duct cancer. About 100 adults with these cancers will provide blood and stool samples to see if certa…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a standard tissue biopsy. Researchers will enroll 200 adults with advanced biliary tract cancer across multiple hospitals in Korea. The goa…

This study is for people with advanced bile duct cancer who are already scheduled to receive a combination of two drugs, lenvatinib and pembrolizumab. Researchers will collect blood and tumor samples to look for genetic markers that might predict who benefits most from this treat…

This study explores whether certain Helicobacter bacteria (like H. pylori) are more common in people with biliary tract cancers compared to those with non-cancerous gallbladder conditions. Researchers will test tissue samples from 250 participants, including cancer patients, peop…